Back to Search
Start Over
Dyskalemia in people at increased risk for heart failure
- Source :
- ESC Heart Failure, ESC Heart Failure, 2022, 9 (6), pp.4352-4357. ⟨10.1002/ehf2.14086⟩, Esc heart failure, 9(6), 4352-4357. John Wiley & Sons Inc.
- Publication Year :
- 2022
-
Abstract
- AIMS: In people at risk of heart failure (HF) enrolled in the Heart 'OMics' in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored factors associated with dyskalaemia. METHODS AND RESULTS: The HOMAGE trial was an open-label study comparing spironolactone (up to 50 mg/day) versus standard care in people at risk for HF. After randomization, serum potassium was assessed at 1 and 9 months and was defined as low when ≤3.5 mmol/L (hypokalaemia) and high when ≥5.5 mmol/L (hyperkalaemia). Multivariable logistic regression models were constructed to identify clinical predictors of dyskalaemia. A total of 513 participants (median age 74 years, 75% men, median estimated glomerular filtration rate 71 mL/min/1.73 m2 ) had serum potassium available and were included in this analysis. At randomization, 88 had potassium 5.0 mmol/L. During follow-up, on at least one occasion, a serum potassium 5.0 mmol/L was observed in 38 (8%) and >5.5 mmol/L in 5 (1.0%) participants. The median (percentile25-75 ) increase in serum potassium with spironolactone during the study was 0.23 (0.16; 0.29) mmol/L. Because of the low incidence of dyskalaemia, for regression analysis, hypokalaemia and hyperkalaemia thresholds were set at 5.0 mmol/L, respectively. The occurrence of a serum potassium > 5.0 mmol/L during follow-up was positively associated with the presence of diabetes mellitus {odds ratio [OR]: 1.21 [95% confidence interval (CI) 2.14; 3.79]} and randomization to spironolactone (OR: 2.83 [95% CI 1.49; 5.37]). Conversely, the occurrence of a potassium concentration
- Subjects :
- Hyperkalaemia
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
heart failure prevention
hyperkalaemia
hypokalaemia
steroidal mineralocorticoid receptor antagonist
Heart failure prevention
Cardiology and Cardiovascular Medicine
Hypokalaemia
Steroidal mineralocorticoid receptor antagonist
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Subjects
Details
- Language :
- English
- ISSN :
- 20555822
- Volume :
- 9
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Esc heart failure
- Accession number :
- edsair.doi.dedup.....c1763a627e81e3bd1b926e0b3d2c2bbe